Numerous disease-modifying therapies (DMTs) have entered the multiple sclerosis (MS) disease landscape in recent years, and many of them are next-generation alternatives within existing classes. Most recently, TG Therapeutics launched Briumvi, the third-in-class anti-CD20 monoclonal antibody. Given the rapid pace of expansion in the MS market, developers of both current and emerging DMTs must continually reassess their products’ differentiation and likely positioning in this highly competitive space. This report will explore neurologists’ perceptions of established and recently launched DMTs, their prescribing habits in today’s market, and anticipated changes in brand usage as more DMTs expand—and further complicate—prescriber choice.
Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
Markets covered: United States
Primary research: Survey of 100 U.S. neurologists
Key drugs covered: Aubagio, Briumvi, glatiramer acetate, Gilenya, interferons, Kesimpta, Lemtrada, Mavenclad, Mayzent, Ocrevus, Ponvory, Tecfidera, Tysabri, Vumerity, Zeposia
Key companies: Biogen, Bristol Myers Squibb, EMD Serono, Genentech, Janssen, Novartis, Roche, Sanofi Genzyme, TG Therapeutics
Key insights provided: